Gene-injected Performance

Dr Matthew During of Auckland University is part of a US medical team promoting the groundbreaking use of gene therapy in the treatment of Parkinson’s disease. Speaking in New York, During emphasised that the procedure was designed to treat rather than cure the disease, by injecting patients with a gene designed to quiet the overstimulated brain activity that causes Parkinson’s. The first recipient of the radical new treatment – 55-year-old New Yorker, Nathan Klein – appears to be recovering well.